American Journal of Dermatopathology · 2022 · 16 citations · 5 references
MedicineDermatologyOncologyChemotherapyDermatopathologyHypersensitivityDermal ToxicityDermatologic Toxicity ManagementImmunopathology Of SkinToxicity ManagementAntibody-drug Conjugate AntibodiesChemotherapy-induced Dermatologic ToxicityCutaneous NecrosisDermatologic Adverse EventsDermatopathologic Lesion DescriptionEpidermal ToxicityHistologic ExaminationSkin Erythema
ABSTRACT: Enfortumab vedotin is an antibody-drug conjugate used for treatment of urothelial cancer. It has recently been associated with several reports of Stevens Johnson syndrome/toxic epidermal necrolysis (TEN). In this report, we describe the case of a 63-year-old man who developed widespread, near full-thickness desquamation, clinically mimicking TEN but with histologic features of toxic erythema of chemotherapy. This distinction is significant because it may have implications for prognosis and treatment. Further investigation is needed to ascertain the incidence of true TEN versus clinical imitators in patients with enfortumab vedotin-related cutaneous toxicity.
5
Paul V. Viscuse, Mario L. Marques‐Piubelli, Meghan Heberton et al. · Frontiers in Oncology · 2021 · 50 citations · Full text
Medicine, Dermatology, Oncology +17
A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
Andrea Francis, Antonio Jimenez, Swaminathan Sundaresan et al. · JAAD Case Reports · 2020 · 26 citations · Full text
Medicine, Oncology, Pharmacology +17
Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition
Sabrina M. Smith, Philip Milam, Stephanie K. Fabbro et al. · JAAD Case Reports · 2016 · 24 citations · Full text
Medicine, Dermatology, Oncology +17